| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
15,692 |
14,413 |
$1.94M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,270 |
1,550 |
$871K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,771 |
4,041 |
$691K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,081 |
4,874 |
$460K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,766 |
2,448 |
$346K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,120 |
1,772 |
$328K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,869 |
2,518 |
$326K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,003 |
830 |
$317K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
3,160 |
775 |
$285K |
| 70450 |
Computed tomography, head or brain; without contrast material |
855 |
745 |
$246K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,160 |
856 |
$157K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,763 |
1,556 |
$148K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
423 |
356 |
$139K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
612 |
571 |
$126K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
657 |
371 |
$123K |
| 80053 |
Comprehensive metabolic panel |
5,337 |
4,077 |
$71K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
285 |
248 |
$71K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
209 |
185 |
$66K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
580 |
492 |
$58K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
519 |
189 |
$49K |
| G0378 |
Hospital observation service, per hour |
522 |
172 |
$39K |
| 71046 |
Radiologic examination, chest; 2 views |
1,254 |
1,152 |
$32K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
146 |
127 |
$31K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
407 |
242 |
$31K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
632 |
580 |
$29K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,009 |
3,306 |
$25K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,188 |
7,894 |
$24K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,362 |
1,205 |
$23K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,671 |
1,436 |
$23K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
83 |
68 |
$21K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
842 |
748 |
$21K |
| 82607 |
|
764 |
663 |
$18K |
| 80061 |
Lipid panel |
1,257 |
1,126 |
$18K |
| 84439 |
|
1,085 |
940 |
$16K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,366 |
2,785 |
$16K |
| 36415 |
Collection of venous blood by venipuncture |
6,679 |
5,410 |
$16K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
437 |
411 |
$14K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,095 |
985 |
$14K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
148 |
130 |
$14K |
| 73562 |
|
482 |
408 |
$12K |
| 97162 |
|
167 |
138 |
$12K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
233 |
216 |
$10K |
| 73630 |
|
466 |
394 |
$10K |
| 85027 |
|
1,014 |
871 |
$10K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
74 |
66 |
$9K |
| 83735 |
|
2,640 |
1,816 |
$8K |
| 73130 |
|
397 |
322 |
$8K |
| 96367 |
|
155 |
96 |
$7K |
| 82570 |
|
670 |
586 |
$7K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
35 |
28 |
$7K |
| 73610 |
|
393 |
334 |
$7K |
| 82728 |
|
412 |
338 |
$7K |
| 73030 |
|
242 |
206 |
$7K |
| 86140 |
|
452 |
359 |
$6K |
| 72100 |
|
162 |
151 |
$6K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
816 |
717 |
$5K |
| 90791 |
Psychiatric diagnostic evaluation |
52 |
29 |
$5K |
| 74018 |
|
135 |
109 |
$5K |
| 83540 |
|
466 |
380 |
$4K |
| 83970 |
|
137 |
112 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
1,999 |
1,719 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,181 |
1,600 |
$4K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,715 |
2,050 |
$4K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
203 |
177 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
354 |
324 |
$3K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
234 |
216 |
$3K |
| 80076 |
|
955 |
772 |
$3K |
| 83550 |
|
388 |
320 |
$3K |
| 94729 |
|
38 |
37 |
$3K |
| 76830 |
Ultrasound, transvaginal |
137 |
121 |
$3K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
121 |
37 |
$3K |
| 81001 |
|
762 |
628 |
$3K |
| 83880 |
|
556 |
456 |
$3K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
13 |
12 |
$2K |
| 27096 |
|
45 |
38 |
$2K |
| 82043 |
|
321 |
292 |
$2K |
| 12001 |
|
13 |
13 |
$2K |
| 84484 |
|
2,260 |
1,781 |
$2K |
| 73110 |
|
93 |
80 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
203 |
177 |
$2K |
| 85610 |
|
1,881 |
1,270 |
$2K |
| 99215 |
Prolong outpt/office vis |
25 |
17 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
128 |
113 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
39 |
39 |
$2K |
| 81003 |
|
3,191 |
2,750 |
$2K |
| 96376 |
|
987 |
518 |
$1K |
| 82746 |
|
119 |
87 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,484 |
1,713 |
$1K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
22 |
12 |
$1K |
| 85652 |
|
231 |
192 |
$1K |
| 85379 |
|
828 |
705 |
$1K |
| 97161 |
|
50 |
46 |
$1K |
| 83690 |
|
1,820 |
1,405 |
$983.34 |
| 84100 |
|
257 |
137 |
$963.26 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
248 |
226 |
$941.87 |
| 73502 |
|
49 |
48 |
$911.11 |
| 84550 |
|
170 |
146 |
$853.21 |
| 84156 |
|
159 |
136 |
$832.29 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
27 |
26 |
$640.13 |
| 80069 |
|
33 |
26 |
$576.41 |
| 99442 |
|
44 |
33 |
$562.76 |
| 90715 |
|
40 |
28 |
$554.25 |
| 82077 |
|
498 |
419 |
$546.72 |
| 85730 |
|
709 |
588 |
$464.72 |
| 87040 |
|
273 |
213 |
$441.83 |
| 81025 |
|
1,586 |
1,306 |
$368.83 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
13 |
13 |
$325.83 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,288 |
1,124 |
$298.07 |
| 73080 |
|
14 |
12 |
$294.79 |
| 87077 |
|
196 |
174 |
$258.18 |
| 83605 |
|
906 |
706 |
$199.33 |
| 87186 |
|
45 |
44 |
$168.54 |
| 86803 |
|
13 |
12 |
$155.77 |
| 94664 |
|
220 |
198 |
$102.65 |
| 82803 |
|
114 |
90 |
$99.74 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,261 |
1,888 |
$94.93 |
| 73590 |
|
14 |
13 |
$86.73 |
| 80143 |
|
44 |
39 |
$59.86 |
| 82550 |
|
17 |
14 |
$56.81 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
393 |
232 |
$43.59 |
| 84145 |
|
63 |
51 |
$33.94 |
| J7050 |
Infusion, normal saline solution, 250 cc |
315 |
165 |
$25.58 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
916 |
715 |
$20.63 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
446 |
388 |
$19.62 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
150 |
144 |
$18.56 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
77 |
72 |
$17.05 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
212 |
149 |
$11.47 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
780 |
578 |
$9.20 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
59 |
40 |
$8.76 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
108 |
79 |
$8.40 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
71 |
59 |
$2.82 |
| J2704 |
Injection, propofol, 10 mg |
418 |
362 |
$2.13 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
306 |
269 |
$1.80 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
68 |
57 |
$1.17 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
14 |
13 |
$1.11 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
391 |
240 |
$0.03 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
39 |
37 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
152 |
134 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
14 |
13 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
24 |
12 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
43 |
29 |
$0.00 |
| A9270 |
Non-covered item or service |
29 |
25 |
$0.00 |
| 94760 |
|
12 |
12 |
$0.00 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
61 |
52 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
14 |
14 |
$0.00 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
12 |
12 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
22 |
14 |
$0.00 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
29 |
27 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
28 |
24 |
$0.00 |
| 80179 |
|
15 |
14 |
$0.00 |